OREX Volume Alert - OREX 4.64 Orexigen Therapeutics $OREX Hit a high of 4.70 Currently 11:15 Last price 4.64 +0.79 +20.52% With a day low of 4.04 and a current volume of 3,713,906.
OREX Orexigen Therapeutics Recent Headline News
Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 18 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 4.97 (+1.12)
Orexigen rises as weight loss drug review proceeds
AP - 1 hr 43 mins ago
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 4.97 (+1.12), VVUS: 3.26 (-0.07), ARNA: 4.29 (+0.03)
Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - 2 hrs 12 mins ago
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 4.97 (+1.12)
Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 4.97 (+1.12)
Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 4.97 (+1.12), YY: 81.38 (+1.88), WDAY: 94.56 (unch), SSYS: 104.09 (+1.02), HKTV: 11.30 (+0.43)
Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 4.97 (+1.12)
Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 4.97 (+1.12)
Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 4.97 (+1.12)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 4.97 (+1.12), ARNA: 4.29 (+0.03)
Orexigen Therapeutics Analyst Coverage Initiated with Price Target by BrokerBank Securities, Inc.
PR Newswire - Thu Oct 23, 6:00AM CDT
Obesity is a serious and growing condition with as many as 2 billion people worldwide considered to be overweight. The World Health Organization further estimates that approximately 500 million of those people are categorized as obese. In the United States alone, more than one-third of all adults are considered to be obese, costing the US healthcare system an estimated $150 billion each year.
OREX: 4.97 (+1.12)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 110.47 (-2.30), OREX: 4.97 (+1.12), HALO: 9.06 (-0.06), LGND: 53.60 (-0.34)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 19.21 (+0.03), OREX: 4.97 (+1.12), VVUS: 3.26 (-0.07), ARNA: 4.29 (+0.03)
Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
PR Newswire - Mon Oct 20, 7:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Contrave is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia).
OREX: 4.97 (+1.12)
Netflix and Baker Hughes are big market movers
AP - Thu Oct 16, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
MDP: 50.59 (+0.39), RJET: 13.03 (+0.43), DAL: 42.97 (+0.28), BAC: 17.33 (-0.03), KEY: 13.41 (+0.02), NFLX: 386.33 (+2.17), OREX: 4.97 (+1.12), MAT: 31.54 (-0.13), CHK: 23.01 (-0.40), SHPG: 200.93 (+2.35), LAKE: 13.23 (-0.06), MSO: 4.14 (+0.09), SWN: 35.81 (-0.69), BHI: 51.85 (-0.45)
Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Thu Oct 16, 12:37PM CDT
Orexigen announced that it has earned a milestone payment of $70 million from its partner Takeda Pharmaceutical Company Limited.
MDVN: 110.47 (-2.30), OREX: 4.97 (+1.12), LGND: 53.60 (-0.34)
Critical Alerts For NewLink Genetics, Orexigen Therapeutics, JinkoSolar, Randgold Resources and Arrowhead Research Released By InvestorsObserver
PR Newswire - Thu Oct 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NLNK, OREX, JKS, GOLD and ARWR.
OREX: 4.97 (+1.12), ARWR: 6.43 (+0.37), GOLD: 65.09 (-2.24), NLNK: 33.26 (+1.11), JKS: 23.16 (-0.08)
Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch
PR Newswire - Wed Oct 15, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related to the shipment of Contrave® (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. The milestone is payable within 30 days of invoice. On October 7, Orexigen received from Takeda $30 million in milestone payments that were earned in September with the approval of Contrave by the United States Food and Drug Administration and the delivery to Takeda of Contrave launch supplies. Orexigen expects to end 2014 with approximately $190 million in cash, cash equivalents and marketable securities.
OREX: 4.97 (+1.12)
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
PR Newswire - Tue Oct 14, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), IsoRay Inc. (NYSE MKT: ISR), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 13, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 16,321.07, down 1.35% and the NASDAQ Composite closed at 4,213.66, down 1.46%. The S&P 500 finished the session 1.65% lower at 1,874.74. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 711.21, down 2.39%, whereas the index has advanced 10.73% on YTD basis. Register for your complimentary reports on these five stocks at:
OREX: 4.97 (+1.12), GILD: 107.49 (+1.04), ISR: 1.57 (-0.02), SNSS: 1.59 (-0.04), MNKD: 5.86 (+0.08)
ORBC, ESSA, OREX, DRR, EPI, EUO Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Oct 09, 6:53AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ORBCOMM Inc (NASDAQ:ORBC), ESSA Bancorp Inc (NASDAQ:ESSA), Orexigen Therapeutics Inc (NASDAQ:OREX), MARKET VECTORS DBL SHORT EUR (NYSE
RR), WisdomTree India Earnings Fund (NYSE:EPI), Eurocontrol Technics Group Inc (NYSE:EUO) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
OREX: 4.97 (+1.12), EPI: 23.12 (-0.09), ORBC: 5.90 (+0.10), ESSA: 11.56 (unch), EUO: 20.56 (+0.11), DRR: 47.34 (+0.36)
OREX Orexigen Therapeutics Recent Headline News
Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 18 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 4.97 (+1.12)
Orexigen rises as weight loss drug review proceeds
AP - 1 hr 43 mins ago
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 4.97 (+1.12), VVUS: 3.26 (-0.07), ARNA: 4.29 (+0.03)
Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - 2 hrs 12 mins ago
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 4.97 (+1.12)
Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 4.97 (+1.12)
Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 4.97 (+1.12), YY: 81.38 (+1.88), WDAY: 94.56 (unch), SSYS: 104.09 (+1.02), HKTV: 11.30 (+0.43)
Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 4.97 (+1.12)
Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 4.97 (+1.12)
Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 4.97 (+1.12)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 4.97 (+1.12), ARNA: 4.29 (+0.03)
Orexigen Therapeutics Analyst Coverage Initiated with Price Target by BrokerBank Securities, Inc.
PR Newswire - Thu Oct 23, 6:00AM CDT
Obesity is a serious and growing condition with as many as 2 billion people worldwide considered to be overweight. The World Health Organization further estimates that approximately 500 million of those people are categorized as obese. In the United States alone, more than one-third of all adults are considered to be obese, costing the US healthcare system an estimated $150 billion each year.
OREX: 4.97 (+1.12)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 110.47 (-2.30), OREX: 4.97 (+1.12), HALO: 9.06 (-0.06), LGND: 53.60 (-0.34)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 19.21 (+0.03), OREX: 4.97 (+1.12), VVUS: 3.26 (-0.07), ARNA: 4.29 (+0.03)
Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
PR Newswire - Mon Oct 20, 7:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Contrave is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). OREX: 4.97 (+1.12)
Netflix and Baker Hughes are big market movers
AP - Thu Oct 16, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
MDP: 50.59 (+0.39), RJET: 13.03 (+0.43), DAL: 42.97 (+0.28), BAC: 17.33 (-0.03), KEY: 13.41 (+0.02), NFLX: 386.33 (+2.17), OREX: 4.97 (+1.12), MAT: 31.54 (-0.13), CHK: 23.01 (-0.40), SHPG: 200.93 (+2.35), LAKE: 13.23 (-0.06), MSO: 4.14 (+0.09), SWN: 35.81 (-0.69), BHI: 51.85 (-0.45)
Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Thu Oct 16, 12:37PM CDT
Orexigen announced that it has earned a milestone payment of $70 million from its partner Takeda Pharmaceutical Company Limited.
MDVN: 110.47 (-2.30), OREX: 4.97 (+1.12), LGND: 53.60 (-0.34)
Critical Alerts For NewLink Genetics, Orexigen Therapeutics, JinkoSolar, Randgold Resources and Arrowhead Research Released By InvestorsObserver
PR Newswire - Thu Oct 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NLNK, OREX, JKS, GOLD and ARWR.
OREX: 4.97 (+1.12), ARWR: 6.43 (+0.37), GOLD: 65.09 (-2.24), NLNK: 33.26 (+1.11), JKS: 23.16 (-0.08)
Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch
PR Newswire - Wed Oct 15, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related to the shipment of Contrave® (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. The milestone is payable within 30 days of invoice. On October 7, Orexigen received from Takeda $30 million in milestone payments that were earned in September with the approval of Contrave by the United States Food and Drug Administration and the delivery to Takeda of Contrave launch supplies. Orexigen expects to end 2014 with approximately $190 million in cash, cash equivalents and marketable securities.
OREX: 4.97 (+1.12)
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
PR Newswire - Tue Oct 14, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), IsoRay Inc. (NYSE MKT: ISR), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 13, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 16,321.07, down 1.35% and the NASDAQ Composite closed at 4,213.66, down 1.46%. The S&P 500 finished the session 1.65% lower at 1,874.74. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 711.21, down 2.39%, whereas the index has advanced 10.73% on YTD basis. Register for your complimentary reports on these five stocks at:
OREX: 4.97 (+1.12), GILD: 107.49 (+1.04), ISR: 1.57 (-0.02), SNSS: 1.59 (-0.04), MNKD: 5.86 (+0.08)
ORBC, ESSA, OREX, DRR, EPI, EUO Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Oct 09, 6:53AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ORBCOMM Inc (NASDAQ:ORBC), ESSA Bancorp Inc (NASDAQ:ESSA), Orexigen Therapeutics Inc (NASDAQ:OREX), MARKET VECTORS DBL SHORT EUR (NYSE
RR), WisdomTree India Earnings Fund (NYSE:EPI), Eurocontrol Technics Group Inc (NYSE:EUO) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: OREX: 4.97 (+1.12), EPI: 23.12 (-0.09), ORBC: 5.90 (+0.10), ESSA: 11.56 (unch), EUO: 20.56 (+0.11), DRR: 47.34 (+0.36)
